Finance

Lists
BLTE:NASDAQ
Belite Bio Inc
USD 153,26
-1,93%
(-3,02) 1D
24 Jul., 14:57:30 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BLTE...
Open
USD 157,11
High
USD 157,11
Low
USD 152,15
Mkt. cap
6,14 mjd
Avg. vol.
201,87 k
Volume
103,24 k
52-wk high
USD 200,00
52-wk low
USD 60,00
EPS
-USD 2,65
Beta
-1,23
Shares outstanding
39,96 m
No. of employees
41
Open
USD 157,11
High
USD 157,11
Low
USD 152,15
Mkt. cap
6,14 mjd
Avg. vol.
201,87 k
Volume
103,24 k
52-wk high
USD 200,00
52-wk low
USD 60,00
EPS
-USD 2,65
Beta
-1,23
Shares outstanding
39,96 m
No. of employees
41
News stories
From sources across the web
About Belite Bio Inc
CEO-
Employees41
Founded2016
Headquarters-
SectorPharmaceutical industry
Websitebelitebio.com
Analyst ratings
Based on 5 analysts giving stock ratings to BLTE in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for BLTE in the last 3 months.
Highest
Current USD 153,26
USD 266,00 (+73,56%)
Average
USD 216,20 (+41,07%)
Lowest
USD 200,00 (+30,50%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yi Chen
H.C. Wainwright
Buy
Reiterated
USD 200,00
+30,5%
07/22/2026
Graig Suvannavejh
Mizuho Securities
Buy
Reiterated
USD 215,00
+40,3%
07/13/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
USD 200,00
+30,5%
06/15/2026
Michael Okunewitch
Maxim Group
Buy
Maintained
USD 200,00
+30,5%
05/27/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
USD 266,00
+73,6%
05/20/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
USD 217,00
+41,6%
03/03/2026
Judah Frommer
Morgan Stanley
Buy
Maintained
USD 201,00
+31,1%
03/03/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun. 2025
Sep. 2025
Des. 2025
Mrt. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
11,05 m
10,31 m
14,62 m
15,66 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,55 m
12,71 m
13,45 m
17,02 m
Operating expense
17,60 m
23,02 m
28,08 m
32,68 m
Total operating expenses
17,60 m
23,02 m
28,08 m
32,68 m
Operating income
-17,60 m
-23,02 m
-28,08 m
-32,68 m
Other non operating income
1,28 m
-2,14 m
-417,00 k
5,75 m
EBT including unusual items
-16,32 m
-21,69 m
-25,32 m
-26,94 m
EBT excluding unusual items
-16,32 m
-21,69 m
-25,32 m
-26,94 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-16,32 m
-21,69 m
-25,32 m
-26,94 m
Net profit margin
-
-
-
-
Earnings per share
-0,50
-0,65
-0,70
-0,68
Interest and investment income
-
3,47 m
3,17 m
-
Interest expense
-
-
-2,00 k
-
Net interest expenses
-
3,47 m
3,17 m
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-17,55 m
-22,97 m
-28,03 m
-32,64 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer